These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21163950)

  • 1. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III.
    Jiang H; Wang H; Tan Z; Hu S; Wang H; Shi B; Yang L; Li P; Gu J; Wang H; Li Z
    J Biol Chem; 2011 Feb; 286(7):5913-20. PubMed ID: 21163950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III.
    Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H
    Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
    Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
    Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.
    Xu W; Bi Y; Kong J; Zhang J; Wang B; Li K; Tian M; Pan X; Shi B; Gu J; Jiang H; Kong X; Li Z
    Oncotarget; 2016 Apr; 7(17):24752-65. PubMed ID: 27029073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.
    Liu L; Qin S; Zheng Y; Han L; Zhang M; Luo N; Liu Z; Gu N; Gu X; Yin X
    Cancer Biol Ther; 2017 Mar; 18(3):166-176. PubMed ID: 28368741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12.
    Dong Q; Shi B; Zhou M; Gao H; Luo X; Li Z; Jiang H
    Front Med; 2019 Feb; 13(1):83-93. PubMed ID: 30671888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
    Cui W; Gu F; Hu KQ
    World J Gastroenterol; 2009 Apr; 15(16):1943-50. PubMed ID: 19399925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
    Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency.
    Li N; Chu Y; Yao L; Ying X; Jiang H; Zhou M; Xu C
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1455-61. PubMed ID: 21809030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
    Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
    Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib and erlotinib inhibits growth of c-Met
    Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
    Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
    Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
    Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.